

Patient First Name

RAVINDER

Patient Last Name

. SINGH

Patient Mobile Number

9868320338

Patient E-mail ID

r.ravi2336@live.com

Date of Birth

02-05-1985

Gender

male

Client

ARCOFEMI HEALTHCARE LIMITED

Agreement Name

(1) ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN INDIA OP AGREEMENT

Package Name

(1) ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Visit Type

in-clinic

Visit Status

Show

Report Status

Order partially completed

City

Clinic

SOHNA ROAD

Order Date

01-03-2024

Appointment Date

09-03-2024

Slot Time

08:45-09:00



Net Amount

1000

Appointment ID

377760

Ref_Appointment ID

UBOIE3917

Visit ID



भारत सरकार
Government of India



रविन्द्र सिंह
Ravinder Singh
जन्म तिथि/DOB: 01/04/1984
पुरुष/ MALE



2695 7258 6401

VID: 9171 9049 7204 4560

मेरा आधार, मेरी पहचान

DATE- 09/03/24

NAME - Ravinder Singh

PHONE -

AGE/GENDER - M

ADDRESS -

EMAIL - R.RAVI2333@live.com

CORPORATE NAME -

1. Past medical history & medications:- NO

2. Any existing disease:- NO

3. Current medications :- NO

4. VITALS - (To be filled by medical personnel)

- BLOOD PRESSURE - 149/90 mm
- PULSE RATE - 82 b/min
- TEMPERATURE - 98.8°f
- SPO2 - 99%
- BLOOD SUGAR (RANDOM) -
- HEIGHT - 5.10 inches (177.8)
- WEIGHT - 71 kg
- BMI - 22.5

vision- Both eye- 6/6

Colour vision- Normal.

5. FINDINGS: -

LAB INVESTIGATION: - TLC - 3790, Disturbed
Lipid profile.

CARDIOLOGY INVESTIGATIONS: - ECG - Normal

RADIOLOGY INVESTIGATIONS: - CX R - Normal.

6. DOCTOR REMARKS: - Abnormal Lipid Profile.


CERTIFICATE OF MEDICAL FITNESS

This is to certify that I have conducted the clinical examination

of Ravinder Singh on 11/3/24.

After reviewing the medical history and on clinical examination it has been found that he/she is

	Tick
<ul style="list-style-type: none"> • Medically Fit 	<input checked="" type="checkbox"/>
<ul style="list-style-type: none"> • Fit with restrictions/recommendations <p>Though following restrictions have been revealed, in my opinion, these are not impediments to the job.</p> <p>1.....</p> <p>2.....</p> <p>3.....</p> <p>However the employee should follow the advice/medication that has been communicated to him/her.</p> <p>Review after _____</p>	<input type="checkbox"/>
<ul style="list-style-type: none"> • Currently Unfit. Review after _____ recommended 	<input type="checkbox"/>
<ul style="list-style-type: none"> • Unfit 	<input type="checkbox"/>

Dr. 
 Medical Officer
 The Apollo Clinic, (Location)

This certificate is not meant for medico-legal purposes

Patient's Name:- MR., RAVINDER
SINGH

Date :- 09/03/2024

Referred By :- HEALTH CHEAKUP

Age/Sex :- 39Y/M

Radiograph of Chest (PA View)

Visualized lungs fields appear normal.

Both hila appear normal

Both CP Angle are clear.

Domes are normally placed.

Cardiac shadow appears normal.

Trachea and mediastinum are normal.

Thoracic bony cage is normal.

Please correlate clinically



Dr Arushi Gupta

MBBS, DNB (Radio - Diagnosis)

Radiologist

09.03.2024 10:45:54
Standard 12-Lead

Name: Ravinder Singh

HR: 79 bpm
P axis: 55°
QRS axis: 24°
T axis: 28°

RR: 761 ms
P: 112 ms
PR: 153 ms
QRS: 93 ms
QT: 327 ms
QTcB: 375 ms


Sinus rhythm
Normal electrical axis
Nonspecific ST abnormality (elevation)
Otherwise normal ECG

Visit ID: [blank]
Room: [blank]
Medication: [blank]
Order ID: [blank]
Ord. prov.: [blank]
Ord. prot.: [blank]

Date of birth: [blank]
Gender: Male
Height: [blank]
Weight: [blank]
Ethnicity: Undefined
Pacemaker: Unknown

Indication: [blank]
Remark: [blank]

Otherwise normal



LP 25Hz, AC 60Hz

Sequential

25 mm/s, 10 mm/mV

LP 25Hz, AC 60Hz

25 mm/s, 10 mm/mV

Patient NAME : MR.RAVINDER SINGH
Age/Gender : 39 Y 0 M 0 D /M
LabNo : DPL21506
Referred BY : SELF
Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
Registration Date : 09/Mar/2024 04:10PM
Sample Collected Date : 09/Mar/2024 04:10PM
Report Generated Date : 09/Mar/2024 05:47PM



DEPARTMENT OF HAEMATOLOGY
APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE BLOOD COUNT				
Sample Type : WHOLE BLOOD EDTA				
HAEMOGLOBIN (HB)	15.30	gm/dL	13.5 - 18.0	Cynmeth Photometric Measurement
RBC COUNT (RED BLOOD CELL COUNT)	4.5	mil/cu.mm	4.7 - 6.0	Electrical Impedence
PCV/HAEMATOCRIT	46.4	%	42-52	Calculated
MCV	102.30	fL	78-100	Electrical Impedence
MCH	33.8	pg	27-31	Calculated
MCHC	33	gm/dL	32-36	Calculated
RDW-SD	14.1	fL	39-46	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	3790	cell/cmm	4000-10000	Electrical Impedence
NEUTROPHIL	51	%	40-80	VCSn Technology
LYMPHOCYTE	40	%	20-40	VCSn Technology
MONOCYTE	07	%	2-10	VCSn Technology
EOSINOPHIL	02	%	1-6	VCSn Technology
BASOPHIL	00	%	0-2	VCSn Technology
PLATELET COUNT	146	10 ³ /ul	150 - 450	Electrical Impedence
MPV	11.7	fL	7.2 - 11.7	Electrical Impedence
PCT	0.2	%	0.2 - 0.5	Calculated
PDW	16.6	%	9.0 - 17.0	Calculated
ABSOLUTE NEUTROPHIL COUNT	1.93	x10 ³ Cells/uL	1.5-7.8	Automated Calculated
ABSOLUTE LYMPHOCYTE COUNT	1.52	x10 ³ Cells/uL	2.0-3.9	Automated Calculated
ABSOLUTE MONOCYTE COUNT	0.27	x10 ³ Cells/uL	0.2-0.95	Automated Calculated
ABSOLUTE EOSINOPHIL COUNT	0.08	x10 ³ Cells/uL	0.2-0.5	Automated Calculated

Tests done on Automated Three Part Cell Counter. (WBC, RBC, Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com

Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME	: MR.RAVINDER SINGH	Barcode NO	: 20010233
Age/Gender	: 39 Y 0 M 0 D /M	Registration Date	: 09/Mar/2024 04:10PM
LabNo	: DPL21506	Sample Collected Date	: 09/Mar/2024 04:10PM
Referred BY	: SELF	Report Generated Date	: 09/Mar/2024 05:47PM
Refer Lab/Hosp	: APOLLO CLINIC		



DEPARTMENT OF HAEMATOLOGY
APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
ERYTHROCYTE SEDIMENTATION RATE				
Sample Type : WHOLE BLOOD EDTA				
ERYTHROCYTE SEDIMENTATION RATE	20	mm/hr	<20	EDTA Whole blood, modified westerngren

Note:

1. Test conducted on EDTA whole blood at 37°C.
2. ESR readings are auto- corrected with respect to Hematocrit (PCV) values.
3. It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever. It is also increased in multiple myeloma, hypothyroidism.

BLOOD GROUP ABO & RH

Sample Type : WHOLE BLOOD EDTA

ABO	A	Gel Columns agglutination
Rh Typing	POSITIVE	Gel agglutination

COMMENTS:

The test will detect common blood grouping system A, B, O, AB and Rhesus (RhD). Unusual blood groups or rare subtypes will not be detected by this method. Further investigation by a blood transfusion laboratory, will be necessary to identify such groups.

Disclaimer: There is no trackable record of previous ABO & RH test for this patient in this lab. Please correlate with previous blood group findings.




Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
Age/Gender : 39 Y 0 M 0 D /M
LabNo : DPL21506
Referred BY : SELF
Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
Registration Date : 09/Mar/2024 04:10PM
Sample Collected Date : 09/Mar/2024 04:10PM
Report Generated Date : 09/Mar/2024 05:28PM



DEPARTMENT OF BIOCHEMISTRY
APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST				
Sample Type : SERUM				
TOTAL BILIRUBIN	0.90	mg/dL	0.1-1.2	Jendrasik Grof
CONJUGATED (D. Bilirubin)	0.20	mg/dL	Adults and Children: < 0.3	Diazotization
UNCONJUGATED (I.D. Bilirubin)	0.70	mg/dL	0.1 - 1.0	Calculated
SGPT	21.50	U/L	< 45	UV with P5P, IFCC 37 Degree
SGOT	26.90	U/L	< 50	UV with P5P, IFCC 37 degree
SGOT/SGPT	1.25	Ratio	0.7 - 1.4	
GGT	18	U/L	< 55	G-glutamyl-carboxy-nitroanilide
ALKALINE PHOSPHATASE	83.00	U/L	56-119	PNPP, AMP Buffer, IFCC 37 degree
TOTAL PROTEINS	7.30	g/dL	6.6-8.3	Biuret, reagent blank end point
ALBUMIN	4.20	g/dL	Adults: 3.5 - 5.2	Bromcresol purple
GLOBULIN	3.1	g/dL	1.8 - 3.6	Calculated
A/G RATIO	1.35	Ratio	1.2 - 2.2	Calculated

Note:

Bilirubin Total

Clinical Significance : "Total Bilirubin is one of the most commonly used tests to assess liver function. A number of inherited and acquired diseases affect bilirubin production, metabolism, storage and excretion and causes hyperbilirubinemia resulting in jaundice. Hyperbilirubinemia may be due to increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Unconjugated hyperbilirubinemia is seen in newborn and known as physiological jaundice. Elevated unconjugated bilirubin in the neonatal period may result in brain damage (kernicterus). Crigler-Najjar syndromes type I and type II are also associated with elevated levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatitis and space-occupying lesions of the liver; and obstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

Bilirubin Direct

Clinical Significance : "Direct bilirubin is a measurement of conjugated bilirubin. Jaundice can occur as a result of increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Inherited disorders in which direct bilirubin levels are increased are seen in Dubin-Johnson syndrome and Rotor syndrome, idiopathic neonatal hepatitis and biliary atresia. The most commonly occurring form of jaundice of the newborn called physiological jaundice is due to increase in levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatocellular diseases such as hepatitis and space-occupying lesions of the liver, obstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

SGOT / AST

Clinical Significance : "Elevated aspartate aminotransferase (AST) values are seen most commonly in parenchymal liver diseases. Values can be elevated from 10 to 100 times the normal range, though commonly 20 to 50 times elevations are seen. AST levels are raised in infectious hepatitis and other inflammatory conditions




Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME	: MR.RAVINDER SINGH	Barcode NO	: 20010233
Age/Gender	: 39 Y 0 M 0 D /M	Registration Date	: 09/Mar/2024 04:10PM
LabNo	: DPL21506	Sample Collected Date	: 09/Mar/2024 04:10PM
Referred BY	: SELF	Report Generated Date	: 09/Mar/2024 05:28PM
Refer Lab/Hosp	: APOLLO CLINIC		

DEPARTMENT OF BIOCHEMISTRY
APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

affecting the liver along with ALT, though ALT levels are higher. The ALT:AST ratio which is normally 1. AST levels are usually raised before clinical signs and symptoms of disease appear. AST and ALT also rise in primary or metastatic carcinoma of the liver, with AST usually being higher than ALT. Elevated AST values may also be seen in disorders affecting the heart, skeletal muscle and kidney, such as myocardial infarction, muscular dystrophy, dermatomyositis, acute pancreatitis and crushed muscle injuries."

SGPT /ALT

Clinical Significance :Elevated alanine aminotransferase (ALT) values are seen in parenchymal liver diseases characterized by a destruction of hepatocytes. Values are at least 10 times higher the normal range and may reach up to 100 times the upper reference limit. Commonly, values are seen to be 20 - 50 times higher than normal. In infectious hepatitis and other inflammatory conditions affecting the liver, ALT levels rise more than aspartate aminotransferase (AST), and the ALT/AST ratio, which is normally 1. ALT levels usually rise before clinical signs and symptoms of disease appear.

Alkaline Phosphatase (ALP)

Clinical Significance :Alkaline Phosphatase levels can be elevated in both liver related as well as bone related conditions. ALP levels are raised (more than 3 fold) in extrahepatic biliary obstruction (eg, by stone or by cancer of the head of the pancreas) than in intrahepatic obstruction, and is directly proportional to the level of obstruction. Levels may rise up to 10 to 12 times the upper limit of normal range and returns to normal on surgical removal of the obstruction. ALP levels rise together with GGT levels and If both GGT and ALP are elevated, a liver source of the ALP is likely. Among bone diseases, ALP levels rise in Paget disease (up to 25 fold),osteomalacia,rickets,primary and secondary hyperparathyroidism and osteogenic bone cancer. Elevated ALP is seen in children following accelerated bone growth. Also, a 2 to 3fold elevation may be observed in women in the third trimester of pregnancy, although the interval is very wide and levels may not exceed the upper limit of the reference interval in some cases.

Total Protein

Clinical Significance :High levels of Serum Total Protein is seen in increased acute phase reactants in inflammation, late-stage liver disease, infections,multiple myeloma and other malignant paraproteinemias.n. Hypoproteinemia is seen in hypogammaglobulinemia, nephrotic syndrome and protein-losing enteropathy.

Albumin

Clinical Significance : "Hypoalbuminemia can be caused by impaired synthesis due to liver disease (primary) or due to diminished protein intake (secondary), increased catabolism due to tissue damage and inflammation; malabsorption of amino acids; and increased renal excretion (eg, nephrotic syndrome).Hyperalbuminemia is seen in dehydration."




Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
 Age/Gender : 39 Y 0 M 0 D /M
 LabNo : DPL21506
 Referred BY : SELF
 Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
 Registration Date : 09/Mar/2024 04:10PM
 Sample Collected Date : 09/Mar/2024 04:10PM
 Report Generated Date : 09/Mar/2024 05:28PM



DEPARTMENT OF BIOCHEMISTRY
 APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



Dr. Sarita Prasad
 MBBS, DNB Pathology
 Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
 Age/Gender : 39 Y 0 M 0 D /M
 LabNo : DPL21506
 Referred BY : SELF
 Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
 Registration Date : 09/Mar/2024 04:10PM
 Sample Collected Date : 09/Mar/2024 04:10PM
 Report Generated Date : 09/Mar/2024 05:28PM



DEPARTMENT OF BIOCHEMISTRY
 APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE				
TOTAL CHOLESTEROL	292.00	mg/dL	Desirable: <= 200 Borderline High: 201-239 High:>239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	Serum, Cholesterol oxidase esterase, peroxidase
TRIGLYCERIDES	387.20	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	Serum, Enzymatic, endpoint
H D L CHOLESTEROL	56.8	mg/dL	Normal: > 40 Major Heart Risk: < 40	Serum, Direct measure-PEG
L D L CHOLESTEROL	157.76	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	Serum
NON HDL CHOLESTEROL	235.2	mg/dL	Desirable: < 130 mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	Calculated
VLDL	77.44	mg/dL	6 - 38	Calculated
T. CHOLESTEROL/ HDL RATIO	5.14	Ratio	3.5 - 5.0	Calculated
LDL / HDL RATIO	2.78	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - >6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated
HDL/LDL RATIO	0.36	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated




Dr. Sarita Prasad
 MBBS, DNB Pathology
 Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
 Age/Gender : 39 Y 0 M 0 D /M
 LabNo : DPL21506
 Referred BY : SELF
 Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
 Registration Date : 09/Mar/2024 04:10PM
 Sample Collected Date : 09/Mar/2024 04:10PM
 Report Generated Date : 09/Mar/2024 05:28PM



DEPARTMENT OF BIOCHEMISTRY
 APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



Dr. Sarita Prasad
 MBBS, DNB Pathology
 Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
 Age/Gender : 39 Y 0 M 0 D /M
 LabNo : DPL21506
 Referred BY : SELF
 Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
 Registration Date : 09/Mar/2024 04:10PM
 Sample Collected Date : 09/Mar/2024 04:10PM
 Report Generated Date : 09/Mar/2024 04:47PM



DEPARTMENT OF BIOCHEMISTRY
 APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE - FASTING				
Sample Type : FLOURIDE PLASMA				
Plasma Glucose Fasting	96.8	mg/dL	Normal: 70-100 Impaired Fasting Glucose (IFG): 100-125 Diabetes Mellitus: >= 126 (On more than one occasion)	Plasma, Hexokinase

Note:

As per American Diabetic Association,(ADA) 2018 Guidelines:
 Fasting Plasma Glucose Value (in mg/dl) Interpretation

- 70 - 100 Normal
- 101 - 125 IFG (Impaired Fasting Glucose)
- >= 126 Diabetes mellitus

It is recommended that fasting plasma glucose be repeated on Two separate occasions or fasting plasma glucose with HbA1c should be done to confirm the diagnosis of Diabetes mellitus.

Fasting is defined as no caloric intake for at least 8 hours




Dr. Sarita Prasad
 MBBS, DNB Pathology
 Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
 Age/Gender : 39 Y 0 M 0 D /M
 LabNo : DPL21506
 Referred BY : SELF
 Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
 Registration Date : 09/Mar/2024 04:10PM
 Sample Collected Date : 09/Mar/2024 04:10PM
 Report Generated Date : 09/Mar/2024 04:47PM



DEPARTMENT OF BIOCHEMISTRY
 APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE- PP				
Sample Type : FLOURIDE PLASMA (PP)				
Plasma Glucose PP	94	mg/dl	80-140	Glucose Oxidase/Peroxidase

INTERPRETATION:

Increased In

- Diabetes Mellitus
- Stress (e.g., emotion, burns, shock, anesthesia)
- Acute pancreatitis
- Chronic pancreatitis
- Wernicke encephalopathy (vitamin B1 deficiency)
- Effect of drugs (e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides)

Decreased In

- Pancreatic disorders
- Extrapancreatic tumors
- Endocrine disorders
- Malnutrition
- Hypothalamic lesions
- Alcoholism
- Endocrine disorders



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



Dr. Sarita Prasad
 MBBS, DNB Pathology
 Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
Age/Gender : 39 Y 0 M 0 D /M
LabNo : DPL21506
Referred BY : SELF
Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
Registration Date : 09/Mar/2024 04:10PM
Sample Collected Date : 09/Mar/2024 04:10PM
Report Generated Date : 09/Mar/2024 05:28PM



DEPARTMENT OF BIOCHEMISTRY
APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
KIDNEY FUNCTION TEST				
Sample Type : SERUM				
SERUM UREA	23.90	mg/dL	17-43	Urease GLDH
Blood Urea Nitrogen (BUN)	11.17	mg/dL	7-18	Urease
SERUM URIC ACID	4.90	mg/dL	3.5-7.2	Uricase/POD
SERUM CREATININE	1.10	mg/dL	0.67-1.17	Jaffe IDMS
SERUM TOTAL CALCIUM	9.20	mg/dL	8.8-10.6	Arsenazo III
SERUM SODIUM	143.8	mmol/L	136-146	ISE
SERUM POTASSIUM	4.25	mmol/L	3.5-5.1	ISE
SERUM CHLORIDE	107.2	mmol/L	101-109	ISE

Note:

Blood Urea Nitrogen (BUN)

Clinical Significance : Increased blood urea nitrogen (BUN) may be due to prerenal causes (cardiac decompensation, water depletion due to decreased intake and excessive loss, increased protein catabolism, and high protein diet), renal causes (acute glomerulonephritis, chronic nephritis, polycystic kidney disease, nephrosclerosis, and tubular necrosis) and postrenal causes (eg, all types of obstruction of the urinary tract, such as stones, enlarged prostate gland, tumors).

Creatinine

Clinical Significance : Serum creatinine is inversely correlated with glomerular filtration rate (GFR). Increased levels of Serum Creatinine is associated with renal dysfunction.

Calcium

Serum Calcium levels are used to monitor and diagnose a wide range of diseases of bone, kidney, parathyroid gland, or gastrointestinal tract. Calcium levels may also reflect abnormal vitamin D or protein levels. Hypocalcemia or low serum calcium levels is associated with absent or decreased function of the parathyroid glands, impaired vitamin-D synthesis, low dietary intake and chronic renal failure. Hypercalcemia is due to increased mobilization of calcium from the skeletal system or increased intestinal absorption. It is usually seen in case of primary hyperparathyroidism (pHPT) or bone metastasis of carcinoma of the breast, prostate, thyroid gland, or lung.

Sodium

Clinical Significance : Serum Sodium estimation is performed to assess acid-base balance, water balance, water intoxication, and dehydration.

Potassium



Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME	: MR.RAVINDER SINGH	Barcode NO	: 20010233
Age/Gender	: 39 Y 0 M 0 D /M	Registration Date	: 09/Mar/2024 04:10PM
LabNo	: DPL21506	Sample Collected Date	: 09/Mar/2024 04:10PM
Referred BY	: SELF	Report Generated Date	: 09/Mar/2024 05:28PM
Refer Lab/Hosp	: APOLLO CLINIC		

DEPARTMENT OF BIOCHEMISTRY
APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

Clinical Significance : Potassium (K+) is the major intracellular cation. It regulates neuromuscular excitability, heart contractility, intracellular fluid volume, and hydrogen ion concentration. High levels of serum Potassium is seen in acute renal disease and end-stage renal failure due to decreased excretion. Levels are also high during the diuretic phase of acute tubular necrosis, during administration of non-potassium sparing diuretic therapy, and during states of excess mineralocorticoid or glucocorticoid.

Chloride

Clinical Significance : Chloride (Cl) is the major extracellular anion and it has an important role in maintaining proper body water distribution, osmotic pressure, and normal anion-cation balance in the extracellular fluid compartment. Chloride is increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfunction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Hyperchloremia acidosis may be a sign of severe renal tubular pathology. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting, aldosteronism, bromide intoxication, syndrome of inappropriate antidiuretic hormone secretion, and conditions associated with expansion of extracellular fluid volume."



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
Age/Gender : 39 Y 0 M 0 D /M
LabNo : DPL21506
Referred BY : SELF
Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
Registration Date : 09/Mar/2024 04:10PM
Sample Collected Date : 09/Mar/2024 04:10PM
Report Generated Date : 09/Mar/2024 05:16PM



DEPARTMENT OF HORMONE ASSAYS
APOLLO PACKAGE 5

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE (T3,T4,TSH)				
Sample Type : SERUM				
T3	1.26	ng/mL	0.79 - 1.58	CLIA
T4	8.97	µg/dl	4.9 - 11.00	CLIA
TSH	2.70	µIU/m	0.38 - 4.31	FIA

Interpretation

It is recommended to interpret serum TSH levels with thyroid hormone levels (especially T4 levels) taking into consideration the clinical status of patient. Pitfalls in the interpretation of the serum TSH alone are in patients with recent treatment for thyrotoxicosis, non-thyroidal illness(acute severe illness or chronic illness), central hypothyroidism, confounding medications.

Condition	TSH	T4	T3
Primary Hypothyroidism	Increased	Low	Normal /Low
Subclinical Hypothyroidism	Increased	Normal	Normal
Primary Hyperthyroidism	Decreased	Increased	Increased
T3 Toxicosis	Decreased	Normal	Increased
Subclinical Hyperthyroidism	Decreased	Normal	Normal
Central Hyperthyroidism/ Thyroid Hormone Resistance	Increased /Normal	Increased	Increased
Central Hypothyroidism / Non Thyroidal Illness	Decreased /Normal	Decreased	Decreased



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



Dr. Sarita Prasad
MBBS, DNB Pathology
Sr. Consultant (HMC.9669)

83
84

Patient NAME : MR.RAVINDER SINGH
 Age/Gender : 39 Y 0 M 0 D /M
 LabNo : DPL21506
 Referred BY : SELF
 Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010233
 Registration Date : 09/Mar/2024 04:10PM
 Sample Collected Date : 09/Mar/2024 04:10PM
 Report Generated Date : 09/Mar/2024 05:25PM



DEPARTMENT OF CLINICAL PATHOLOGY
 APOLLO PACKAGE5

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE ROUTINE EXAMINATION				
VOLUME	20	ml	-	
COLOUR	PALE YELLOW		PALE YELLOW	
TRANSPARENCY	CLEAR		Clear	
REACTION (PH)	6.50		4.5 - 7.0	
SPECIFIC GRAVITY	1.025		1.010 - 1.030	
CHEMICAL EXAMINATION				
URINE SUGAR.	ABSENT		Nil	
Urine Protein	ABSENT		Nil	
Urine Ketones	ABSENT		Nil	
BLOOD	ABSENT		Absent	
Leukocyte esterase	ABSENT		Negative	
Bile pigments	ABSENT		Absent	
NITRITE	ABSENT		Negative	
UROBILINOGEN	ABSENT		Normal	
MICROSCOPIC EXAMINATION				
PUS CELLS	3-4	/hpf	0 - 5	
EPITHELIAL CELLS	2-3	/hpf	0 - 5	
RBCs	ABSENT	/hpf	Absent	
CRYSTALS	ABSENT		Absent	
CASTS	ABSENT		Absent	
OTHER	ABSENT			

*** End Of Report ***



email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



Dr. Sarita Prasad
 MBBS, DNB Pathology
 Sr. Consultant (HMC.9669)

83
84